sb-525334 has been researched along with Fibrosis* in 5 studies
5 other study(ies) available for sb-525334 and Fibrosis
Article | Year |
---|---|
The local wound environment is a key determinant of the outcome of TGFβ signaling on the fibrotic response of CD44
The cytokine transforming growth factor beta (TGFβ) has a role in regulating the normal and pathological response to wound healing, yet how it shifts from a pro-repair to a pro-fibrotic function within the wound environment is still unclear. Using a clinically relevant ex vivo post-cataract surgery model that mimics the lens fibrotic disease posterior capsule opacification (PCO), we investigated the influence of two distinct wound environments on shaping the TGFβ-mediated injury response of CD44 Topics: Actins; Animals; Blotting, Western; Capsule Opacification; Cataract Extraction; Cell Proliferation; Chick Embryo; Collagen Type I; Disease Models, Animal; Fibronectins; Fibrosis; Hyaluronan Receptors; Imidazoles; Integrin alphaVbeta3; Microscopy, Fluorescence; Myofibroblasts; Posterior Capsule of the Lens; Postoperative Complications; Pyrazoles; Pyrroles; Quinoxalines; Receptor, Transforming Growth Factor-beta Type I; Signal Transduction; Transforming Growth Factor beta; Wound Healing | 2021 |
Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.
Muscular fibrosis is caused by excessive accumulation of extracellular matrix (ECM) that replaces functional tissue, and it is a feature of several myopathies and neuropathies. Knowledge of the biology and regulation of pro-fibrotic factors is critical for the development of new therapeutic strategies. Upon unilateral sciatic nerve transection, we observed accumulation of ECM proteins such as collagen and fibronectin in the denervated hindlimb, together with increased levels of the profibrotic factors transforming growth factor type β (TGF-β) and connective tissue growth factor (CTGF/CCN2). In mice hemizygous for CTGF/CCN2 or in mice treated with a blocking antibody against CTGF/CCN2, we observed reduced accumulation of ECM proteins after denervation as compared to control mice, with no changes in fibro/adipogenic progenitors (FAPs), suggesting a direct role of CTGF/CCN2 on denervation-induced fibrosis. During time course experiments, we observed that ECM proteins and CTGF/CCN2 levels are increased early after denervation (2-4 days), while TGF-β signaling shows a delayed kinetics of appearance (1-2 weeks). Furthermore, blockade of TGF-β signaling does not decrease fibronectin or CTGF levels after 4 days of denervation. These results suggest that in our model CTGF/CCN2 is not up-regulated by canonical TGF-β signaling early after denervation and that other factors are likely involved in the early fibrotic response following skeletal muscle denervation. Topics: Animals; Antibodies, Monoclonal, Humanized; Benzamides; Connective Tissue Growth Factor; Dioxoles; Extracellular Matrix; Fibrosis; Gene Expression Regulation; Imidazoles; Male; Mice; Models, Animal; Muscle Denervation; Muscle, Skeletal; Quinoxalines; Signal Transduction; Transforming Growth Factor beta | 2019 |
MicroRNA-214 antagonism protects against renal fibrosis.
Renal tubulointerstitial fibrosis is the common end point of progressive renal disease. MicroRNA (miR)-214 and miR-21 are upregulated in models of renal injury, but the function of miR-214 in this setting and the effect of its manipulation remain unknown. We assessed the effect of inhibiting miR-214 in an animal model of renal fibrosis. In mice, genetic deletion of miR-214 significantly attenuated interstitial fibrosis induced by unilateral ureteral obstruction (UUO). Treatment of wild-type mice with an anti-miR directed against miR-214 (anti-miR-214) before UUO resulted in similar antifibrotic effects, and in vivo biodistribution studies demonstrated that anti-miR-214 accumulated at the highest levels in the kidney. Notably, in vivo inhibition of canonical TGF-β signaling did not alter the regulation of endogenous miR-214 or miR-21. Whereas miR-21 antagonism blocked Smad 2/3 activation, miR-214 antagonism did not, suggesting that miR-214 induces antifibrotic effects independent of Smad 2/3. Furthermore, TGF-β blockade combined with miR-214 deletion afforded additional renal protection. These phenotypic effects of miR-214 depletion were mediated through broad regulation of the transcriptional response to injury, as evidenced by microarray analysis. In human kidney tissue, miR-214 was detected in cells of the glomerulus and tubules as well as in infiltrating immune cells in diseased tissue. These studies demonstrate that miR-214 functions to promote fibrosis in renal injury independent of TGF-β signaling in vivo and that antagonism of miR-214 may represent a novel antifibrotic treatment in the kidney. Topics: Animals; Disease Models, Animal; Fibrosis; Gene Deletion; Gene Expression; Humans; Imidazoles; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Quinoxalines; Renal Insufficiency, Chronic; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Ureteral Obstruction | 2014 |
Ex vivo micro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation.
Research into the pathogenesis underlying the development of idiopathic pulmonary fibrosis is hampered by a repertoire of animal models that fail to recapitulate all the features of the human disease. Better use and understanding of what the animal models represent may improve clinical predictability. We interrogated ex vivo micro-computed tomography (CT) as a novel end-point measure in the mouse model of bleomycin-induced lung fibrosis (BILF), and to evaluate a therapeutic dosing regimen for preclinical drug evaluation. A detailed characterisation of BILF was performed using standard end-point measures (lung hydroxyproline and histology). High resolution micro-CT (∼13.7 μm voxel size) was evaluated for quantifying the extent and severity of lung fibrosis. The period from 14 to 28 days following bleomycin instillation represents progression of established fibrosis. A therapeutic dosing regimen during this period was validated using a transforming growth factor-β receptor-1 kinase inhibitor, and micro-CT provided a highly sensitive and quantitative measure of fibrosis. Moreover, fibrotic lesions did not completely resolve, but instead persisted for ≥6 months following a single insult with bleomycin. Ex vivo micro-CT analysis of BILF allows robust evaluation of therapeutic dosing once fibrosis is already well established, requiring fewer mice than conventional biochemical end-points. Topics: Animals; Bleomycin; Chromatography, High Pressure Liquid; Collagen; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Fibrosis; Humans; Imidazoles; Lung; Male; Mice; Mice, Inbred C57BL; Protein Serine-Threonine Kinases; Pulmonary Fibrosis; Quinoxalines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Treatment Outcome; X-Ray Microtomography | 2013 |
Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29.
Fibrosis pathophysiology is critically regulated by Smad 2- and Smad 3-mediated transforming growth factor-β (TGF-β) signaling. Disintegrin metalloproteases (Adam) can manipulate the signaling environment, however, the role and regulation of ADAMs in renal fibrosis remain unclear. TGF-β stimulation of renal cells results in a significant up-regulation of Adams 10, 17, 12, and 19. The selective Smad2/3 inhibitor SB 525334 reversed these TGF-β-induced changes. In vivo, using ureteral obstruction to model renal fibrosis, we observed increased Adams gene expression that was blocked by oral administration of SB 525334. Similar increases in Adam gene expression also occurred in preclinical models of hypertension-induced renal damage and glomerulonephritis. miRNAs are a recently discovered second level of regulation of gene expression. Analysis of 3' untranslated regions of Adam12 and Adam19 mRNAs showed multiple binding sites for miR-29a, miR-29b, and miR-29c. We show that miR-29 family expression is decreased after unilateral ureter obstruction and this significant decrease in miR-29 family expression was observed consistently in preclinical models of renal dysfunction and correlated with an increase in Adam12 and Adam19 expression. Exogenous overexpression of the miR-29 family blocked TGF-β-mediated up-regulation of Adam12 and Adam19 gene expression. This study shows that Adams are involved in renal fibrosis and are regulated by canonical TGF-β signaling and miR-29. Therefore, both Adams and the miR-29 family represent therapeutic targets for renal fibrosis. Topics: Animals; Cell Line; Disintegrins; Fibrosis; Gene Expression Regulation, Enzymologic; Glomerulonephritis; Imidazoles; Male; Mice; MicroRNAs; Quinoxalines; Rats; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta | 2013 |